Six people got a single IV drip engineered to find HIV hiding inside their cells and physically cut it out. That sentence alone would have sounded like science fiction five years ago. EBT-101, developed by Excision BioTherapeutics from foundational work at Temple University, is the first FDA-cleared in-vivo CRISPR therapy targeting HIV. Its early results, presented at the International AIDS Conference 2024, land somewhere between thrilling and sobering.
- EBT-101 uses AAV9 — a viral delivery vehicle — to carry CRISPR-Cas9 molecular scissors into cells harboring dormant HIV proviral DNA
- The scissors target conserved regions of the HIV genome, specifically LTR sequences (regulatory regions) and the gag gene (a structural region), to excise integrated viral code
- Delivered as a single intravenous infusion; participants continued antiretroviral therapy (ART) for 12 weeks, then some stopped meds under medical supervision
- Six participants split across two dose levels: 0.9 × 10¹² and 3 × 10¹² vector genomes per kilogram
Rachel Presti of Washington University described the results as “important clinical evidence that a gene editing treatment modality can be safely delivered for targeting the HIV DNA reservoirs in human cells,” according to aidsmap.com reporting.
Across all six participants: zero serious adverse events. Nine mild side effects total. No detected off-target DNA damage — CRISPR cut where instructed and nowhere else. For a therapy permanently editing the genome of otherwise clinically stable individuals, that safety record is the headline regulators and investors needed.
Here’s the gut punch. Four participants stopped ART. All four saw HIV return.
One stood out: a single participant showed delayed rebound at roughly 16 weeks — considerably longer than typical rebound timelines — alongside measurable frozen brain tissue reservoir shrinkage. One person. One signal. Not a cure, but the kind of anomaly that keeps researchers awake at night for the right reasons.
Version Two
Guide RNA mismatches and single-dose limitations explain the gap between animal models and human results — and point precisely toward what needs to change.
Where the science gets complicated: EBT-101’s guide RNAs were designed for HIV subtype B but had sequence mismatches against some participants’ actual viral strains, reducing editing efficiency across the board. Think of it like a first-generation streaming service — functional, genuinely important, but essentially a detailed blueprint for what version two needs to fix. Chantelle Ahlenstiel of the Kirby Institute described the trial as “a high-risk study that showed a very promising safety profile,” while stressing that next-generation guide RNAs conserved across all HIV subtypes are the essential next step, per EATG reporting. Independent virologists echo that combining reservoir editing with complementary strategies — CCR5 gene editing or broadly neutralizing antibodies — may ultimately be necessary for durable remission.
Roughly 40 million people manage HIV daily with pills that work reliably. The goal is making those pills unnecessary. EBT-101 didn’t get there. It proved the road exists — and mapped exactly where the potholes are.
